These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35384046)

  • 1. Rituximab-induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review.
    Charoenpipatsin N; Chularojanamontri L; Rujitharanawong C; Tuchinda P; Kulthanan K
    J Dermatol; 2022 Aug; 49(8):e251-e252. PubMed ID: 35384046
    [No Abstract]   [Full Text] [Related]  

  • 2. Childhood pemphigus foliaceus presenting as a polycyclic eruption: Case report and review of the literature.
    Evans MS; Culton DA; Diaz LA; Googe PB; Morrell DS
    Pediatr Dermatol; 2019 Mar; 36(2):236-241. PubMed ID: 30762246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome mining and B cell depletion support a role for B cells in psoriasis pathophysiology.
    Toussi A; Merleev A; Barton VR; Le ST; Marusina A; Luxardi G; Kirma J; Xing X; Adamopoulos IE; Fung MA; Raychaudhuri SP; Shimoda M; Gudjonsson JE; Maverakis E
    J Dermatol Sci; 2019 Dec; 96(3):181-184. PubMed ID: 31780313
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective case-control study of clinical factors associated with paradoxical exacerbation of pemphigus vulgaris following rituximab infusion.
    Narayanan A; Ramam M; Bhari N
    Int J Dermatol; 2020 Dec; 59(12):e459-e460. PubMed ID: 33197052
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab induced reticulate pigmentation over face in pemphigus vulgaris.
    Sanke S; Mendiratta V; Jassi R; Yadav J; Chander R
    Dermatol Ther; 2020 Jul; 33(4):e13752. PubMed ID: 32519811
    [No Abstract]   [Full Text] [Related]  

  • 6. Juvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab.
    Yousif J; Gottlieb AB; Al-Dehneem R
    J Drugs Dermatol; 2023 Aug; 22(8):830-831. PubMed ID: 37556511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy in pemphigus: A long-term follow-up.
    Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
    Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris.
    Foschi CM; Maloney C; Amber KT
    J Dtsch Dermatol Ges; 2022 Apr; 20(4):520-521. PubMed ID: 35322556
    [No Abstract]   [Full Text] [Related]  

  • 9. Septic shock in a refractory pemphigus vulgaris patient after rituximab therapy.
    Lima RB; Manhães MB; de Souza Felix M; Gonçalves MLC
    Dermatol Ther; 2021 Jan; 34(1):e14725. PubMed ID: 33377269
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory pemphigus foliaceous treated with rituximab.
    Awdeh F; Gilhooley E; O Grady C; Connolly M
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31147410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing full dose and half dose of rituximab in relapsing pemphigus patients.
    Saleh MA; Saleh NA
    Dermatol Ther; 2020 Nov; 33(6):e14349. PubMed ID: 32981111
    [No Abstract]   [Full Text] [Related]  

  • 12. Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients.
    Mazaherpour E; Kianfar N; Dasdar S; Sedaghat M; Seyrafi H; Balighi K; Saberi F; Nili A; Farimani Z; Azar PM; Mahmoodi H; Murrell DF; Daneshpazhooh M
    Dermatol Ther; 2022 Dec; 35(12):e15902. PubMed ID: 36200713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of pemphigus by varicella zoster virus after anti-CD20 treatment.
    Douard PA; Delaumenie S; Pittoni J; Assikar S; Matei I; Prudhomme R; Audevard D; Bédane C
    Int J Dermatol; 2020 Mar; 59(3):e52-e53. PubMed ID: 31840226
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris.
    Boch K; Langan EA; Schmidt E; Zillikens D; Ludwig RJ; Bieber K; Hammers CM
    Acta Derm Venereol; 2022 Mar; 102():adv00679. PubMed ID: 35312020
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of cardiac function in patients with pemphigus vulgaris before and after rituximab infusion.
    Jafari M; Pighgahi M; Shahidi-Dadras M; Ghalamkarpour F; Tehranchinia Z; Abdollahimajd F; Moravvej H; Robati RM; Mozafari N; Namazi N; Diab R; Razzaghi Z; Toudeshki KK; Dadkhahfar S; Nasiri S
    Arch Dermatol Res; 2024 May; 316(5):170. PubMed ID: 38734780
    [No Abstract]   [Full Text] [Related]  

  • 16. Transient worsening of pemphigus vulgaris resembling toxic epidermal necrolysis after the first cycle of rituximab therapy.
    Mokos M; Lakoš Jukić I; Marinović B
    Dermatol Ther; 2022 Jun; 35(6):e15469. PubMed ID: 35332629
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies.
    Schultz B; Latour E; Fett N
    Br J Dermatol; 2019 Nov; 181(5):1101-1103. PubMed ID: 31127954
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of reported infectious events following rituximab therapy in pemphigus patients.
    Shahrigharahkoshan S; Dadkhahfar S; Mozafari N; Shahidi-Dadras M
    Dermatol Ther; 2022 Mar; 35(3):e15264. PubMed ID: 34907628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab.
    Wei KC; Wang YH; Wang WH; Chen W
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e350-e351. PubMed ID: 28129481
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Ferranti M; Tadiotto Cicogna G; Sattin A; Alaibac M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.